Loading…
Loading…
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") is pleased to announce its intention to complete a non-brokered private placement of convertible debentures of the Company (the "Debentures") in an aggregate principal amount of up to $500,000, issuable in increments of $1,000 principal amount, for aggregate gross proceeds of up to $500,000 (the "Offering"). The Offering is expected to close on or about August 28, 2026 (the "Closing Date").
Vancouver, British Columbia--(Newsfile Corp. - August 18, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) ("Noveris" or the "Company") is pleased to announce that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for the Company's U.S. Patent Application No. 18/443,025, titled "Aza-Substituted Psilocin Analogs and Methods of Synthesizing the Same.
Vancouver, British Columbia--(Newsfile Corp. - August 6, 2026) - At the request of CIRO, Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity. Noveris is a Canadian life sciences company focused on opportunities in mental health and therapeutic innovation.
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") announces that it has become a member of BioAlberta, a not-for-profit industry association representing Alberta's life sciences community. BioAlberta supports its members through industry development, educational and networking activities, and engagement on matters affecting Alberta's life sciences sector.
VANCOUVER, BC, Canada – TheNewswire - July 17, 2026 — Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) (“Noveris” or the “Company”) is pleased to announce that it has joined the Biotechnology Innovation Organization (“BIO”), the world's largest advocacy association representing biotechnology companies, academic and research institutions, state and regional biotechnology centers and related organizations across the United States and in more than 35 other countries. By joining BIO, Noveris is strengthening its participation in the global biotechnology ecosystem and expanding opportunities to engage with industry leaders, strategic partners, investors and policymakers across the United States and internationally. The Company believes that membership in BIO will support greater visibility for Noveris within the broader biotechnology and life sciences community while providing access to BIO's policy committees, investor and partnering events, industry research and cost-savings programs that help foster collaboration and commercialization.
VANCOUVER, BC, Canada – TheNewswire - July 14, 2026 — Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) ("Noveris" or the "Company") is pleased to announce that, effective July 13, 2026, it has joined Life Sciences British Columbia ("Life Sciences BC" or "LSBC"), the not-for-profit industry association that supports and represents British Columbia's life sciences community through leadership, investment, advocacy and promotion. By joining LSBC, Noveris is strengthening its participation in British Columbia's life sciences ecosystem and expanding opportunities to engage with innovators, strategic partners, investors, advisors and other sector stakeholders across the province. The Company believes that membership in LSBC will support greater visibility for Noveris within the local and national life sciences community while providing access to networking, industry programming and initiatives that help foster collaboration and commercialization.
VANCOUVER, BC, Canada – TheNewswire - June 29, 2026 — Noveris Health Sciences Inc. (CSE: NVRS; FSE: 0NF0; OTC: MYCOF) (“ Noveris ” or the “ Company ”) is pleased to announce that its annual general meeting of shareholders (the " Meeting ") will be held on September 4, 2026 at 1890-1075 West Georgia Street, Vancouver, British Columbia. The record date for the meeting has been set for July 21, 2026. At the Meeting, shareholders of the Company will be asked to consider and, if deemed advisable, approve the following matters:
Vancouver, British Columbia – June 12, 2026 – TheNewswire – Noveris Health Sciences Inc. (“Noveris” or the “Company”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce the appointment of Nathan Mison as Chair of the Company's Advisory Board. The Advisory Board has been established by the Company's Board of Directors to provide management and the Board with access to additional external expertise as the Company continues its strategic review of its intellectual property portfolio and related opportunities. The Advisory Board is intended to serve in an advisory capacity only and will not have decision-making authority on behalf of the Company. Its mandate includes providing strategic input, identifying potential opportunities, supporting management's assessment of relevant industry, regulatory, partnership and commercialization matters, and recommending additional advisory candidates whose expertise may support the Company's strategic objectives.
No recent filings indexed.